IBI306
Sponsors
Innovent Biologics (Suzhou) Co. Ltd., Shenzhen People's Hospital
Conditions
Familial Hypercholesterolemia - HomozygousHeterozygous Familial HypercholesterolemiaHomozygous Familial HypercholesterolemiaHypercholesterolemiaLipid Metabolism DisordersNon-Familial Hypercholesterolemia and Mixed HyperlipidemiaProprotein Convertase Subtilisin/Kexin 9
Phase 1
Phase 2
Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia
CompletedNCT03815812
Start: 2019-03-07End: 2019-12-25Updated: 2023-11-18
A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia
CompletedNCT04031742
Start: 2019-09-29End: 2021-12-30Updated: 2023-08-09
Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia
NCT04948008
Start: 2019-11-05End: 2022-12-31Target: 8Updated: 2021-07-01
Phase 3
Safety and Efficacy of IBI306 in HeFH Patients
CompletedNCT04179669
Start: 2019-12-20End: 2021-06-30Updated: 2023-08-09
A Study of IBI306 in Participants With Hypercholesterolemia
CompletedNCT04709536
Start: 2021-02-09End: 2022-01-28Updated: 2024-10-31
IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
Active, not recruitingNCT07473960
Start: 2026-04-01End: 2027-02-28Updated: 2026-08-14